RELEASE: Pharmadule Morimatsu and WuXi Biologics Reach Global Strategic Partnership

SHANGHAI, June 27, 2023/PRNewswire/ -- On June 26, 2023, Pharmadule Morimatsu and WuXi Biologics officially entered into a global strategic cooperation for the WuXi Biologics Singapore CRDMO Center project.

RELEASE: Pharmadule Morimatsu and WuXi Biologics Reach Global Strategic Partnership

SHANGHAI, June 27, 2023/PRNewswire/ -- On June 26, 2023, Pharmadule Morimatsu and WuXi Biologics officially entered into a global strategic cooperation for the WuXi Biologics Singapore CRDMO Center project.

As leaders in their respective fields, this strategic partnership marks an important milestone in the growth and development of the business of both companies. In addition, it is a strategic step to help its customers around the world. Looking ahead, WuXi Biologics and Pharmadule Morimatsu will continue to explore new opportunities for cooperation and collaboration on a global scale.

WuXi Biologics is a world leading CRDMO company. Leveraging its comprehensive open access platform, WuXi Biologics provides its clients around the world with comprehensive research, development and manufacturing services for monoclonal, bispecific antibodies, ADCs, vaccines and other biologics. Since 1986, Pharmadule Morimatsu has successfully supplied more than 80 modular installations to the pharmaceutical and biopharmaceutical industries around the world. In recent years, Pharmadule Morimatsu has delivered a large number of modular production modules and skids for the production of different types of advanced biological medicines to the United States, China, Morocco, Egypt, Mexico and other countries. Pharmadule Morimatsu provides customers with "basic equipment/machinery value-added digitized intelligence of global plant solutions and services" ("MVP Solutions and Services"), giving customers confidence in achieving rapid commercial production and faster time to market.

This strategic cooperation begins with the integrated modular plant of two major production facilities at WuXi Biologics' Singapore CRDMO Center, and will include design, manufacturing, FAT, installation, commissioning and validation. The project will adopt a new generation of modular manufacturing, with most of the works being built, assembled and FAT tested in the Morimatsu workshop. Project quality, schedule, cost and risk will be well managed and controlled. Compared with conventional construction, this method also greatly shortens the project cycle.

Chris Chen, CEO of WuXi Biologics, commented: "Singapore is one of the world's most advanced pharmaceutical hubs, as well as a key part of our global biomanufacturing network. By leveraging the knowledge and experience of Pharmadule Morimatsu, we are confident that our Singapore CRDMO Center will add to our track record of establishing successful global centers, as demonstrated by our greenfield center in Ireland, while also enabling global partners to receive world-class services and solutions."

Weihua Tang, CEO of Morimatsu LifeSciences, explained, "WuXi Biologics is an important partner of our company, we are delighted to cooperate with them once again. In this cooperation, Pharmadule Morimatsu will use a new generation of modular manufacturing methods to help WuXi Biologics to expand its production capacity, accelerate the empowerment of global pharmaceutical companies, reduce R&D costs, and benefit patients around the world."

About WuXi Biologics

WuXi Biologics (Stock Code: 2269.HK) is one of the world's leading Contract Research, Development and Manufacturing Organizations (CRDMOs) providing end-to-end solutions that enable its partners to discover, develop and manufacture biologics, from conception to completion. commercialization, for the benefit of patients around the world.

With more than 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions.

WuXi Biologics regards environmental, social and governance (ESG) responsibilities as an integral component of our ethics and business strategy, and we aim to become an ESG leader in the biologics CRDMO industry. Our facilities use state-of-the-art biomanufacturing technologies and clean energy sources. We have also established an ESG committee led by our CEO to drive the comprehensive ESG strategy and its implementation, enhancing our commitment to sustainability.

For more information about WuXi Biologics, please visit:

About Morimatsu Life Sciences

Morimatsu LifeSciences is a subsidiary of Morimatsu International Holdings Limited (Morimatsu International, Stock Code: 2155.HK), covering Pharmaceutical, Biopharmaceutical, FMCG, Cosmetic, E-Chemical and other sectors, provides customers with "value-added basic equipment/machinery Digitized Intelligence of Global Plant Solutions and Services" ("MVP Solutions and Services"), including mainly Shanghai Morimatsu Pharmaceutical Equipment Engineering Co, LTD., Morimatsu (Suzhou) LifeSciences Co., LTD., Shanghai Morimatsu Biotechnology Co. ., LTD., and Pharmadule Morimatsu AB., Morimatsu Pharmadule (Singapore) Private Limited, as well as their affiliates. Morimatsu LifeSciences focuses on the research and development, manufacturing, and sales of products in related fields.

For more information about Morimatsu LifeSciences, visit:

About Pharmadule Morimatsu

Since its inception in 1986, Pharmadule (a member of the Morimatsu Group since 2011) has supplied more than 80 production facilities in the pharmaceutical and biopharmaceutical industries worldwide, and has completed more than 300 engineering designs and solution validations, resulting in demonstrates that we are the world's leading provider of integrated and holistic facilities as well as equipment for core processes.

For more information about Pharmadule Morimatsu, visit:

forward-looking statements

The information contained in this press release may contain certain forward-looking statements. These statements are inherently subject to considerable risks and uncertainties. When used in connection with the Company, the words "anticipate", "believe", "foresee", "expect", "intend" and other similar expressions are intended to indicate that they are forward-looking statements. The Company does not undertake any obligation to periodically update these forward-looking statements.

These forward-looking statements are based on the current opinions, assumptions, expectations, estimates, projections and understandings of the Company's management regarding future events at the time they were made. These statements are not guarantees of future events and are subject to risks, uncertainties and other factors, some of which are beyond the control of the Company and are difficult to predict. Therefore, actual results may differ materially from the information contained in forward-looking statements, subject to future changes and developments in our business, competitive environment, political, economic, legal and social conditions.

Photo - - Photo - 2141288/3. jpg

View original content: